UNSPSC 51434004: Rilmakalim

This classification denotes an antihypertensive agent with the molecular formula C21H23NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47Y56T6LEI, chemically known as 2-pyrrolidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-2h-1-benzopyran-4-yl)-, (3s-trans)- but generally known as rilmakalim, which bears US NIH Compound Identifier 65966. European Medicines Agency schedules Rilmakalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10314MIG.

UNSPSC 51434004 Rilmakalim, a Commodity code, represents emergency and acute-care pharmaceuticals that state and local governments procure for fire rescue services, health agencies, and multistate cooperative purchasing programs. The code captures direct procurement of branded and generic injectable medications—epinephrine, labetalol, adenosine, diltiazem, and similar advanced life support agents—that paramedics and emergency medical personnel administer in the field. State and local issuing bodies under this code include municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions; the City of Tampa, Texas Health and Human Services Commission, and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are recent active buyers.

Activity spans Florida, Texas, and the upper Midwest, with MMCAP's multistate reach extending to Oregon. Representative recent opportunities include the City of Tampa's IFB (Solicitation 26P00188, due April 8, 2026) seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term renewable for two additional years; MMCAP's RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities, effective July 1, 2026, with a two-year initial term; and the Texas HHS Commission's exploratory RFI (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription programs to inform future procurement strategy. The Tampa bid carries a 5 percent SLBE discount capped at $10,000 and requires OSHA Safety Data Sheets and Section 508 accessibility documentation; MMCAP mandates cGMP and Drug Supply Chain Security Act compliance, specified EDI capability, and insurance minimums including $5,000,000 commercial general liability.